Oncimmune Holdings (LSE:ONC) Cash-to-Debt : 0.17 (As of Feb. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Oncimmune Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Oncimmune Holdings's cash to debt ratio for the quarter that ended in Feb. 2024 was 0.17.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Oncimmune Holdings couldn't pay off its debt using the cash in hand for the quarter that ended in Feb. 2024.

The historical rank and industry rank for Oncimmune Holdings's Cash-to-Debt or its related term are showing as below:

LSE:ONC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08 Med: 0.61 Max: No Debt
Current: 0.17

During the past 12 years, Oncimmune Holdings's highest Cash to Debt Ratio was No Debt. The lowest was 0.08. And the median was 0.61.

LSE:ONC's Cash-to-Debt is ranked worse than
92.67% of 1527 companies
in the Biotechnology industry
Industry Median: 6.24 vs LSE:ONC: 0.17

Oncimmune Holdings Cash-to-Debt Historical Data

The historical data trend for Oncimmune Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Oncimmune Holdings Cash-to-Debt Chart

Oncimmune Holdings Annual Data

Trend

May14

May15

May16

May17

May18

May19

May20

May21

May22

Aug23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

0.51

0.91

0.24

0.61

Oncimmune Holdings Semi-Annual Data
	May14	Nov14	May15	Nov15	May16	Nov16	May17	Nov17	May18	Nov18	May19	Nov19	May20	Nov20	May21	Nov21	May22	Feb23	Aug23	Feb24
Cash-to-Debt	Get a 7-Day Free Trial															0.36	0.24	0.08	0.61	0.17

Competitive Comparison of Oncimmune Holdings's Cash-to-Debt

For the Biotechnology subindustry, Oncimmune Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncimmune Holdings's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncimmune Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Oncimmune Holdings's Cash-to-Debt falls into.

Oncimmune Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Oncimmune Holdings's Cash to Debt Ratio for the fiscal year that ended in Aug. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.209	/	(0.332	+	4.969)
	=	0.61

Oncimmune Holdings's Cash to Debt Ratio for the quarter that ended in Feb. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.911	/	(0.984	+	4.278)
	=	0.17

Oncimmune Holdings (LSE:ONC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Oncimmune Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Oncimmune Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncimmune Holdings (LSE:ONC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncimmune Holdings PLC (LSE:ONC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

OCY:Germany

Address

1 Park Row, MediCity - D6 Building, Leeds, GBR, LS1 5AB

Website

https://www.oncimmune.com

Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacture, and commercialization of personalized immunodiagnostics for the screening, detection and care of cancer. The company's operating segment includes Early CDT Lung and ImmunoINSIGHTS.

Oncimmune Holdings (LSE:ONC) Headlines

No Headlines